

- (1) Includes shares which the Underwriters may purchase to cover over-allotments, if any.
- (2) The registration fee is calculated pursuant to Rule 457(d) under the Securities Act of 1933 based on the initial public offering price of \$18 per share.

THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE UPON FILING WITH THE COMMISSION IN ACCORDANCE WITH RULE 462(B) UNDER THE SECURITIES ACT OF 1933.

EXPLANATORY NOTE AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

This registration statement is being filed with respect to the registration of additional shares of common stock, \$.01 par value per share, of Antigenics Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the registrant's effective registration statement on Form S-1 (File No. 333-91747) are incorporated into this registration statement by reference.

The required opinions and consents are listed on an Exhibit Index and filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, State of New York, on February 3, 2000.

ANTIGENICS INC.

By: /s/ GARO ARMEN

 Garo H. Armen, Ph.D.
 Chief Executive Officer and Chairman
 of
 the Board of Directors

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

SIGNATURE -----	TITLE -----	DATE ----
/s/ GARO ARMEN ----- Garo Armen, Ph.D.	Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer and Principal Financial and Accounting Officer)	February 3, 2000
* ----- Pramod Srivastava, Ph.D.	Director	February 3, 2000
* ----- Noubar Afeyan, Ph.D.	Director	February 3, 2000
* ----- Edward Brodsky	Director	February 3, 2000
* ----- Gamil de Chadarevian	Director	February 3, 2000
* ----- Tom Dechaene	Director	February 3, 2000
* ----- Donald Panoz	Director	February 3, 2000
* ----- Martin Taylor	Director	February 3, 2000

*By: /s/ GARO ARMEN

 As Attorney-in-fact

EXHIBIT INDEX

EXHIBIT NO. -----	TITLE -----
5.1	Opinion of Palmer & Dodge LLP
23.1	Consent of Palmer & Dodge LLP (included in the opinion filed as Exhibit 5.1.)
23.2	Consent of KPMG LLP
24.1*	Power of Attorney

* Filed with the registrant's Registration Statement on Form S-1 (Registration No. 333-91747).

[PALMER & DODGE LLP LETTERHEAD]

TELEPHONE: (617) 573-0100

FACSIMILE: (617) 227-4420

February 3, 2000

Antigenics Inc.
630 Fifth Avenue, Suite 2100
New York, New York 10111

We are rendering this opinion in connection with the Registration Statement on Form S-1 (the "Registration Statement") filed by Antigenics Inc. (the "Company") with the Securities and Exchange Commission under the Securities Act of 1933, as amended, on or about the date hereof. The Registration Statement relates to up to 575,000 shares of the Company's Common Stock, \$0.01 par value per share (the "Shares"). We understand that the Shares are to be offered and sold in the manner described in the Registration Statement.

We have acted as your counsel in connection with the preparation of the Registration Statement. We are familiar with the proceedings of the Board of Directors in connection with the authorization, issuance and sale of the Shares (the "Resolutions"). We have examined such other documents as we consider necessary to render this opinion.

Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued and delivered by the Company against payment therefor at the price to be determined pursuant to the Resolutions, will be validly issued, fully paid and non-assessable.

The foregoing opinion is limited to Delaware General Corporation Law and the federal laws of the United States.

We hereby consent to the filing of this opinion as a part of the Registration Statement and to the reference to our firm under the caption "Legal Matters" in the Prospectus filed as part thereof.

Very truly yours,

/s/ Palmer & Dodge LLP

PALMER & DODGE LLP

INDEPENDENT AUDITORS' CONSENT

The Members and Board of Managers of Antigenics L.L.C.:

We consent to the use of our report incorporated by reference herein, and to the references to our firm under the headings "Selected Consolidated Financial Data" and "Experts" in the Prospectus and Registration Statement.

/s/ KPMG LLP

Short Hills, New Jersey
January 31, 2000